MedTrace Logo

Multi-modal Neuroimaging in Alzheimer's Disease

NCT01554202 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 295

Last updated 2013-03-06

No results posted yet for this study

Summary

According to estimations, Alzheimer's disease affects approximately 860,000 people aged of more than 65 years in France. This disease is characterized by disorders of cognitive functions, including memory, associated with structural and functional modifications of the brain. These changes are evolving within the pathology progression and can be evaluated with neuropsychological tests (to assess capabilities such as language, orientation, etc.) and also with brain imaging (e.g. MRI). Alzheimer's disease is still poorly understood, nevertheless currently available treatments can slow its development if the disease is diagnosed early enough.

Thus, the objective is to identify markers for early diagnosis of Alzheimer's disease, to better describe the evolution of this disease.

The three main objectives of this project are

* to identify, compare and combine predictive markers of Alzheimer's disease
* to make a significant contribution to the understanding of the pathophysiological mechanisms of Alzheimer's disease
* to study the ability of different neuroimaging techniques to follow the evolution of this pathology.

Conditions

Interventions

BEHAVIORAL

assessment of memory

BIOLOGICAL

circulating tPA dosage

GENETIC

ApoE4

OTHER

Brain imaging examination MRI and PET examinations

Sponsors & Collaborators

  • Institut National de la Santé Et de la Recherche Médicale, France

    collaborator OTHER_GOV

  • University Hospital, Caen

    lead OTHER

Principal Investigators

  • Vincent de La Sayette, MD · University Hospital, Caen

Study Design

Allocation
NON_RANDOMIZED
Purpose
DIAGNOSTIC
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2008-01-31
Primary Completion
2021-12-31

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01554202 on ClinicalTrials.gov